Funder
This article is published under the Creative Commons Attribution Non-commercial License.
Publisher
Touch Medical Media, Ltd.
Subject
General Earth and Planetary Sciences
Reference19 articles.
1. U.S. Food and Drug Administration. PRAMIPEXOLE DIHYDROCHLORIDE approval. 1997. Available at: www. accessdata.fda.gov/drugsatfda_docs/nda/98/020667a_appltr.pdf (accessed 2 November 2022).
2. Cudkowicz M, Bozik ME, Ingersoll EW, et al. The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis. Nat Med. 2011;17:1652–6.
3. Cudkowicz ME, van den Berg LH, Shefner JM, et al. Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): A randomised, double-blind, phase 3 trial. Lancet Neurol. 2013;12:1059–67.
4. Dworetzky SI, Hebrank GT, Archibald DG, et al. The targeted eosinophil-lowering effects of dexpramipexole in clinical studies. Blood Cells Mol Dis. 2017;63:62–5
5. Panch SR, Bozik ME, Brown T, et al. Dexpramipexole as an oral steroid-sparing agent in hypereosinophilic syndromes. Blood. 2018;132:501–9.